Hu7691 is primarily investigated for its potential therapeutic applications in the field of oncology. Research suggests it may act as a selective inhibitor targeting specific pathways involved in cancer cell proliferation, making it a promising candidate for the development of anti-cancer drugs. Its mechanism of action is believed to disrupt key cellular processes in tumor cells, potentially leading to reduced tumor growth and metastasis. Additionally, Hu7691 is being studied for its role in enhancing the efficacy of existing chemotherapy regimens, possibly by sensitizing cancer cells to treatment. Preclinical studies are ongoing to evaluate its safety, pharmacokinetics, and overall effectiveness in various cancer models. If successful, it could pave the way for novel targeted therapies in oncology.